H-447 humanized bispecific agent combining Merck's cancer-targeting component and MEDX's immune system trigger: Began Phase I/II dose-escalation trial that will

Medarex Inc. (MEDX), Annandale, N.J. Merck KGaA (Darmstadt, Germany) Product: H-447 humanized bispecific agent combining Merck's cancer-targeting component and MEDX's immune system trigger Indication...